



## Cardiovascular Standing Committee, Post-Comment Web Meeting

---

The National Quality Forum (NQF) convened a public web meeting for the Cardiovascular Standing Committee on September 24, 2019.

### Welcome, Introductions, and Review of Meeting Objectives

NQF welcomed the Standing Committee and participants to the web meeting and provided opening remarks. NQF staff reviewed the meeting objectives:

- Discussion on inconsistent voting results
- Re-vote on eQMs

### Discussion on Inconsistencies

The Standing Committee discussed how initial voting results on the electronic clinical quality measures (eQMs) did not reflect the discussions that took place during the June 19 and 20 spring 2019 measure evaluation web meetings. During the June webinars, the Committee expressed substantial concerns about the effect of the feasibility results on the reliability, validity, and usefulness of the three eQMs under review. The voting results for the eQMs were different from and conflicted with the Committee's discussions and concerns. Additionally, the voting results for reliability, validity, feasibility, and usability were inconsistent among the three eQMs. It was further noted that had voting occurred in real time the inconsistencies would have been immediately addressed by the Co-chairs and NQF staff. Since most of the votes occurred offline due to a lack of quorum, the post-comment web meeting was the first opportunity to discuss the voting results.

After reviewing and discussing the voting inconsistencies, the Standing Committee re-voted on NQF 0070e *Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF<40%)*, NQF 0081e *Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)*, and NQF 0083e *Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) eQm*. The Committee recommended the measures for continued endorsement though they acknowledged feasibility issues due to the variability in electronic health records.

### Public Comment

No public or NQF member comments were provided during the post-comment web meeting.

### Next Steps

The NQF staff informed the Committee that their discussion would be updated in the report and that the Committee's recommendations will be presented at the October 21-22, 2019 CSAC meeting.